A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes

• Published in: British journal of haematology Vol. 103; no. 4; pp. 1070 - 1074
• Main Authors: Ferrini, P R, Grossi, A, Vannucchi, A M, Barosi, G, Guarnone, R, Piva, N, Musto, P, Balleari, E
• Format: Journal Article
• Language: English
• Published: Oxford, U.K. and Cambridge, USA Blackwell Science Ltd 01.12.1998; Blackwell; Blackwell Publishing Ltd
• Subjects: Adult; Aged; anaemia; Biological and medical sciences; Blood. Blood coagulation. Reticuloendothelial system; Double-Blind Method; erythropoietin; Erythropoietin - therapeutic use; Female; Hematology; Humans; Male; Medical sciences; Middle Aged; myelodysplastic syndromes; Myelodysplastic Syndromes - therapy; Pharmacology. Drug treatments; Recombinant Proteins; Risk Factors; transferrin receptor; transfusion; Human; Chemotherapy; Randomization; Treatment; Erythropoietin; Cytokine; Double blind study; Controlled therapeutic trial; Subcutaneous administration; Malignant hemopathy; Glycoprotein hormone; Myelodysplastic syndrome

To evaluate the effect of recombinant human erythropoietin (rHuEpo) on the haemoglobin level and transfusion requirement in low‐risk myelodysplastic syndromes (MDS), 87 patients were enrolled in a randomized double‐blind placebo‐controlled study. 44 patients were assigned to epoetin α (150 U/kg/d s....